Speciality: Oncology
Description:
In this insightful presentation, renowned oncologist Dr. Nagender Sharma delves into the evolving landscape of advanced urothelial carcinoma treatment. With a focus on evidence-based strategies, Dr. Sharma welcomes viewers to explore the latest advancements, clinical trial insights, and personalized approaches that are reshaping patient care. He emphasizes the importance of integrating immunotherapy, targeted therapies, and chemotherapy while addressing challenges like resistance mechanisms and biomarker-driven decision-making. This video serves as a comprehensive guide for clinicians seeking to optimize outcomes in this complex malignancy.
Dr. Sharma meticulously examines cutting-edge therapies such as immune checkpoint inhibitors, antibody-drug conjugates (e.g., enfortumab vedotin), and FGFR inhibitors, highlighting their roles in first-line and subsequent treatments. He discusses real-world applications of combination regimens, patient selection criteria, and the impact of molecular profiling on tailoring therapies. Additionally, he sheds light on emerging trends, including adaptive clinical trial designs and the potential of novel biomarkers to refine prognostic accuracy. His analysis balances optimism with pragmatism, acknowledging hurdles like toxicity management and access disparities.
Concluding with a forward-looking perspective, Dr. Nagender Sharma underscores the collaborative effort required to translate scientific breakthroughs into tangible survival benefits for patients. Viewers are encouraged to watch the full video to gain actionable insights and stay abreast of this rapidly advancing field. Don’t miss this opportunity to learn from a leading expert. Subscribe for future updates and deepen your understanding of oncology’s most pressing challenges.
See More Webinars @ Hidoc Webinars
1.
Children living near oil and gas wells face higher risk of rare leukemia, studies show
2.
Lung nodules seen in a high percentage of non-smokers
3.
AI model combines clinical and magnetic resonance data to improve prediction of breast cancer recurrence
4.
Colon cancer and exercise: Can physical activity reprogram genes?
5.
Black women are more likely to die of breast cancer. Close the gap by looking into mammogram studies.
1.
Understanding QSOFA: A Vital Tool for Recognizing Sepsis
2.
Can Wearables and AI Become a Gamechanger for Histiocytic Cancer Detection?
3.
Understanding Pancreatic Cancer: Symptoms, Causes and Risk Factors
4.
Screening Strategies in Oncology: A Subspecialty Guide to Early Detection and Better Outcomes
5.
CA-125 Test: Why It's Important for Women's Health and Early Detection of Ovarian Cancer
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V
3.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Summarization of the New Perspective
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
5.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation